1. Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer.
- Author
-
Soula M, Unlu G, Welch R, Chudnovskiy A, Uygur B, Shah V, Alwaseem H, Bunk P, Subramanyam V, Yeh HW, Khan A, Heissel S, Goodarzi H, Victora GD, Beyaz S, and Birsoy K
- Subjects
- Animals, Female, Mice, CD8-Positive T-Lymphocytes immunology, Cell Line, Tumor, Cell Proliferation, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use, Interferon gamma Receptor metabolism, Interferon-gamma immunology, Killer Cells, Natural immunology, Mice, Inbred C57BL, Signal Transduction, Lipidomics, Glycosphingolipids biosynthesis, Glycosphingolipids deficiency, Glycosphingolipids immunology, Glycosphingolipids metabolism, Immune Evasion, Neoplasms immunology, Neoplasms metabolism, Neoplasms pathology, Proto-Oncogene Proteins p21(ras) metabolism, Tumor Escape
- Abstract
Cancer cells frequently alter their lipids to grow and adapt to their environment
1-3 . Despite the critical functions of lipid metabolism in membrane physiology, signalling and energy production, how specific lipids contribute to tumorigenesis remains incompletely understood. Here, using functional genomics and lipidomic approaches, we identified de novo sphingolipid synthesis as an essential pathway for cancer immune evasion. Synthesis of sphingolipids is surprisingly dispensable for cancer cell proliferation in culture or in immunodeficient mice but required for tumour growth in multiple syngeneic models. Blocking sphingolipid production in cancer cells enhances the anti-proliferative effects of natural killer and CD8+ T cells partly via interferon-γ (IFNγ) signalling. Mechanistically, depletion of glycosphingolipids increases surface levels of IFNγ receptor subunit 1 (IFNGR1), which mediates IFNγ-induced growth arrest and pro-inflammatory signalling. Finally, pharmacological inhibition of glycosphingolipid synthesis synergizes with checkpoint blockade therapy to enhance anti-tumour immune response. Altogether, our work identifies glycosphingolipids as necessary and limiting metabolites for cancer immune evasion., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2024
- Full Text
- View/download PDF